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Abstract The data presented implicate a GATA binding site in
the transcriptional regulation of 15-lipoxygenase-1 (15-LO-1)
gene expression in human colorectal carcinoma Caco-2 cells.
High expression of GATA-6 mRNA and protein was observed,
while GATA-4 mRNA was expressed at a very low level in Caco-
2 cells. The expression of GATA-6 was down-regulated, while
15-LO-1 expression was dramatically up-regulated after treat-
ment with sodium butyrate (NaBT). A study using an electro-
phoretic mobility shift assay indicated that a GATA binding site
of the 15-LO-1 promoter region binds to GATA proteins present
in both undifferentiated and, to a lesser extent, NaBT-treated
(differentiated) Caco-2 cells. Moreover, that DNA binding shift
band was disrupted after the addition of GATA-6 antibody in a
supershift assay in the absence of NaBT, suggesting that GATA-
6 is bound to the GATA binding site of the 15-LO-1 promoter in
undifferentiated cells. In contrast, the addition of GATA-6
antibody did not affect the DNA binding ability in NaBT-induced
differentiated cells. On the other hand, mutation of the GATA
site of the 15-LO-1 promoter decreased the transactivation of the
15-LO-1 promoter as measured by luciferase activity in both
FBS and NaBT cultured cells, indicating an unknown GATA
binding protein to up-regulate 15-LO-1 expression. These
implicate the GATA site at 3240 of the proximal region of the
15-LO-1 promoter in the basic transcription of 15-LO-1 gene
expression in Caco-2 cells, with GATA-6 acting to repress 15-
LO-1 expression.
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1. Introduction
The GATA family of transcription factors contain one or
two DNA binding zinc ¢nger domains of the distinctive form
C-X-N-C-(X17)-C-N-X-C and recognize the consensus DNA
sequence (A/T)GATA(A/G), which is an essential cis element
in the promoters or enhancers of a variety of genes [1].
GATA-1/2/3 are expressed in the hematopoietic cell lineage
and play critical roles in the development of hematopoietic
stem cells [2]. In contrast, the more recently identi¢ed
GATA-4/5/6 genes represent a subfamily of factors that are
expressed in cardiovascular tissues [3], gut [3^5], urogenital
system [6] and smooth muscle cells [7]. A possible role for
GATA-4/5/6 in regulating gut-speci¢c gene expression is pro-
posed based on the expression of GATA-4/5/6 in the intestinal
tissues. The presence of GATA binding sites has been re-
ported in the K- and L-subunit promoter encoding the H/
K-ATPase in stomach [8,9], rat histidine decarboxylase gene
in gastric endocrine cells [10] and the intestinal fatty acid
binding protein gene in the intestinal derived cells [11]. Fur-
thermore, recent evidence suggests that GATA-4/5/6 are es-
sential for development and di¡erentiation in gut [11^16].
Nevertheless, the precise role of GATA-4/5/6 remains unclear
in intestinal derived cells and tissues.
Lipoxygenases are dioxygenases that incorporate one mol-
ecule of oxygen at a speci¢c position of unsaturated fatty
acids such as arachidonic acid [17]. Among the members of
the lipoxygenase family, reticulocyte-type 15-lipoxygenase (15-
LO-1) [18] is unique in its ability to oxidize complex substrates
such as biomembranes [19]. 15-LO-1 is also expressed during
distinct stages of reticulocyte development [20], in macro-
phages of atherosclerotic lesions [21], in human tracheal epi-
thelial cells during retinoid-induced mucocilial di¡erentiation
[22] and in the eye lens in conjunction with organelle degra-
dation [23]. These reports suggest the possible involvement of
di¡erentiation-related transcription factors in the regulation
of the 15-LO-1 gene. We observed the induction of 15-LO-1
in the human colorectal carcinoma cell line, Caco-2 after
treatment with NaBT, concomitant with cell di¡erentiation
[24], and subsequently in human colorectal carcinoma tissues
[25]. Only a few reports describe the transcriptional regulation
of the 15-LO-1 gene. The 15-LO-1 gene is regulated by cyto-
kines, IL-4 and IL-13 in monocytes [26,27] and in airway cells
[28,29]. A speci¢c Stat6 response element located at 952 base
pairs upstream of the translational start codon is responsible
for the regulation of 15-LO-1 by IL-4 [30]. However, the
regulation of 15-LO-1 by cytokines appears to be di¡erent
from that by NaBT during cell di¡erentiation. Unlike cyto-
kines, butyrate is a short-chain fatty acid, a product of fer-
mentation of luminal carbohydrates, and is found in millimo-
lar concentration in the lumen of the intestinal epithelium
[31]. Moreover, NaBT is often used as a model for cellular
di¡erentiation in intestinal derived cell lines [32].
We focused on transcription factors GATA-4/5/6 for regu-
lation of 15-LO-1 expression in the intestinal derived cells.
The genomic DNA of 15-LO-1 was isolated as a clone and
a part of the sequence of the 5P £anking region was deter-
mined [33,34]. The GATA binding site exists at 3240 of the 5P
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£anking region in 15-LO-1 gene. Thus, based on the possible
involvement of GATA in cell di¡erentiation and the regula-
tion of 15-LO-1 expression during NaBT-induced di¡erentia-
tion, we evaluated the expression of GATA family transcrip-
tion factors, especially GATA-4/5/6. Furthermore, nuclear
extracts from Caco-2 cells were used to study their binding
properties at the GATA binding site. In this study, we report
the presence of a binding protein for the GATA binding site
in the promoter region of the 15-LO-1 gene and present evi-
dence implicating the GATA binding site in the transcription
of 15-LO-1 in Caco-2 cells.
2. Materials and methods
2.1. Cell culture
The human colon carcinoma cell line, Caco-2, was obtained from
the American Type Culture Collection (ATCC). The cells were grown
in Eagle’s minimal essential medium (EMEM)/15% fetal bovine serum
(FBS) supplemented with 1 mM sodium pyruvate (GIBCO/BRL) and
gentamicin (1 mg/100 ml) (GIBCO/BRL). FBS was from Summit and
NaBT was obtained from Sigma. For treating cells with NaBT, cells
were cultured in the appropriate media containing serum until near
con£uency. The medium was removed and replaced with FBS medium
containing NaBT.
2.2. Northern blot analysis
15-LO-1 probe was purchased from Oxford and the G3PDH cDNA
that was used as the internal standard was purchased from Clontech.
The cDNA probes of GATA-4 and GATA-6 were generated by RT-
PCR from the human heart RNA (Clontech) as the template. The
primers and cDNA are as follows: G4S, AACGGAAGCCCAA-
GAACCTGA and G4A, TGCAGTGTGCTCGTGCTGAA for gen-
eration of GATA-4 cDNA which has 613 bp as the predicted size
(GeneBank Accession Number D78260), G6S, AGGCCATTTGGTA-
CACATCTCT and G6A, TAATGTAAACCAACCTGCCTGT for
generation of GATA-6 cDNA that has 641 bp as the predicted size
(GeneBank Accession Number U66075). Both cDNAs were extracted
by using QIAquick gel extraction kit (QIAGEN) after agarose gel
electrophoresis.
Extraction of total RNA from the cells, electrophoresis and hybrid-
ization were preformed as previous described [24].
2.3. Immunoprecipitation and Western blotting
Nuclear extracts from Caco-2 cells were prepared as previously
described [35] and stored at 380‡C. Protein concentration was deter-
mined by the bicinchronic acid method using BCA protein assay
reagent (Pierce). Nuclear extract containing 0.3 mg protein was pre-
cleared with 5 Wl of normal rabbit serum, 20 Wl of protein G-agarose
and 100 Wl of protein A-Sepharose beads. The mixture was tumbled at
4‡C for 1 h, and centrifuged at 10 000Ug for 2 min, and the super-
natant transferred to a new tube. Anti-GATA-4 or anti-GATA-6,
2 Wg of each, was added to the supernatant and the samples were
tumbled for 2 h at 4‡C. For some experiments, 1 Wg of blocking
peptide for anti-GATA-6 or anti-epidermal growth factor receptor
(EGFR; both from Santa Cruz Biotechnology) was also included.
Then, 20 Wl of protein G-agarose (Santa Cruz Biotechnology) and
100 Wl of protein A-Sepharose (Sigma) beads were added and samples
were tumbled for an additional 2 h. After centrifugation at 10 000Ug
for 2 min, the pellet was washed three times with 1 ml of 20 mM
HEPES, pH 7.5, 150 mM NaCl, 0.1% Triton X-100, 10% glycerol.
2Uprotein sample bu¡er was added to the ¢nal pellet, the sample was
boiled for 8 min and centrifuged at 10 000Ug for 10 min. The super-
natant was immediately loaded, run on SDS^PAGE (8% acrylamide
gel) and electrophoretically transferred to a nitrocellulose membrane
in 25 mM Tris, 192 mM glycine, 20% methanol with 0.1% SDS using
Hoefer semi-dry electrophoresis equipment. Membranes were blocked
in Tris-bu¡ered saline containing 0.1% Tween 20 (TBST) with 5%
non-fat milk at 4‡C overnight. The blots were then incubated with
anti-GATA-4 or anti-GATA-6 (1:500) in TBST plus 3% non-fat milk
for 3 h at room temperature. The blots were washed ¢ve times in
TBST and then incubated with horseradish peroxidase-conjugated
anti-goat IgG (1:5000) in TBST containing 3% non-fat milk at
room temperature for 1 h. The blots were again washed ¢ve times
in TBST, and visualized using the Amersham ECL system.
2.4. Electrophoretic mobility shift assays (EMSA)
Three di¡erent oligonucleotide probes were used in this study. The
commercially available oligonucleotide of wild-type, N-GATA,
CGCCGCAGAGATAAGGCACTGCC (Geneka Biotechnology) in-
cluding GATA binding site was used. Two oligonucleotide probes
were synthesized based on the sequence of the promoter region of
15-LO-1 including GATA site: WT-15LO-GATA, TCCCGTCAA-
GATAGTGGTTTCCA (nucleotides 3249 to 3227) and Mu-15LO-
GATA, TCCCGTCAATAT*ATG*GTGGTTTCCA in which GATA
site is mutated. Each complementary oligonucleotide was annealed at
a concentration of 250 mM in 250 mM Tris (pH 7.8) at 95‡C for 15
min and then cooled slowly to room temperature. Probes were labeled
using [Q-32P]ATP (Amersham) and T4 polynucleotide kinase (Pharma-
cia). The GATA-1 gel shift kit was obtained from Geneka Biotech-
nology and the procedure for the reaction between the probe and
nuclear extracts was followed according to the manufacturer’s instruc-
tion. Supershift assays were also performed by preincubating with the
following anti-GATA antibodies, GATA-1 (c-20), GATA-2 (c-20),
GATA-3 (c-18), GATA-4 (c-20), GATA-5 (Y-19) and GATA-6 (c-
20) (all antibodies were purchased from Santa Cruz). Bound and free
probes were resolved by non-denaturing polyacrylamide gel electro-
phoresis. The entire contents of each reaction were loaded onto 5%
polyacrylamide (38:2) gel, pre-cooled to 4‡C in 1UTris^glycine elec-
trophoresis bu¡er. Gels were dried under vacuum on Whatman 3 mm
paper (Whatman) and exposed to X-ray ¢lm.
2.5. Transient transfection and luciferase assay
15-LO-1 promoter/reporter plasmids were constructed in pGL2
(Promega) as previously described [34]. The numbering of nucleotides
in the 5P £anking region of 15-LO-1 was de¢ned by de¢ning the
translational start codon as +1. The location of the transcriptional
initiation site is at 327 [33,34]. In this study, -628/-23pGL2, Mu-
628/-23pGL2 and pGL-Basic (Promega) plasmids were used (Fig.
4A). Mu-628/-23pGL2 plasmid was generated by the technique of
site-directed mutagenesis and has an alternative sequence in the
GATA site. For transfection, cells were plated in 6-well plates at a
density of 1U105 cells/well and incubated in FBS medium for 24 h.
After washing the cells with PBS, 1 Wg of luciferase reporter and 10 ng
of pRL-null internal control construct (Promega) were transfected
using 5 Wl of Lipofectamine (Life Technologies, Inc.). The medium
was replaced after 6 h with or without 5 mM NaBT and the cells were
incubated for 48 h.
The cells were harvested using 500 Wl of passive lysis bu¡er (Prom-
ega). Fire£y luciferase and renilla (sea pansy) luciferase activities were
measured sequentially using a dual-luciferase reporter assay system
(Promega) and a model TD-20/20 Luminometer (Turner Design).
After measuring the ¢re£y luciferase signal (LAF) and the renilla lu-
ciferase signal (LAR), the relative luciferase activity (RLA) was calcu-
lated as RLA = LAF/LAR.
2.6. Site-directed mutagenesis
Mutations were generated by QuikChange site-directed mutagenesis
kit (Stratagene) for Mu-628/-23pGL2. Primer S-GA, TCTCTC-
CTCCCGTCAATTGAGTGGTTTCCACTCCCT and its reverse
complement were used for Pfu polymerase ampli¢cation under con-
ditions speci¢ed by the manufacturer’s instruction. The transformed,
white colonies were picked and plasmid DNA was extracted by SNAP
Miniprep kit (Invitrogen). The product was sequenced to verify the
mutations.
3. Results
3.1. GATA-4 and GATA-6 are expressed in Caco-2 cells
The expressions of GATA-4/5/6 were evaluated in Caco-2
cells. Based on the cDNA sequence indicated in GeneBank,
three sets of primers corresponding to GATA-4/5/6 were syn-
thesized and RT-PCR was performed. GATA-4 and GATA-6
were expressed, while GATA-5 was undetectable (data not
shown). We next measured by Northern analysis the temporal
expression of GATA-4 and 6, as well as 15-LO-1 (Fig. 1A) in
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order to determine the involvement of GATA proteins in
NaBT-induced expression of 15-LO-1. A faint expression of
GATA-4 was observed before and after treatment with NaBT.
The expression was increased by NaBT treatment, although
still weak, and the maximum level was observed 10 h after
treatment. In contrast, a strong expression of GATA-6 was
detected before treatment with NaBT and gradually decreased
after NaBT treatment.
Next, we examined the protein expression of GATA-4/5/6
using nuclear extracts before and after treatment with NaBT.
The expressions of GATA-4 (Fig. 1B) and GATA-5 (data not
shown) were not detectable by Western analysis even with the
concentration of the target protein by immunoprecipitation.
In contrast, GATA-6 expression was clearly observed before
NaBT treatment. NaBT caused a down-regulation of protein
expression of GATA-6 (Fig. 1B), which is consistent with the
temporal change in mRNA expression. GATA-6 expression
was con¢rmed by the speci¢c abrogation of the signal with a
blocking peptide for anti-GATA-6, but not with that for anti-
EGFR. Since 15-LO-1 is up-regulated by NaBT, the changes
in the expression patterns of 15-LO-1 and GATA-6 appear to
occur in opposition with each other.
3.2. Nuclear binding proteins recognize and bind to the GATA
site in Caco-2 cells
Nucleotide sequences in approximately 1 kb of the 5P £ank-
ing region of the promoter area of the 15-LO-1 gene have
been analyzed, and a GATA site is located 240 bp upstream
from the translational start codon [33,34]. Thus, we ampli¢ed
a 979 bp fragment of the promoter region of 15-LO-1 gene
from genomic DNA of Caco-2 cells and the sequence was
determined (data not shown). The GATA site was located
at the same position in Caco-2 cells as previously reported
[33,34]. Then, we tested Caco-2 cells for the presence of a
nuclear protein which was bound to DNA at the GATA
site by EMSA (Fig. 2). Two di¡erent labeled DNA probes
containing the GATA site were used and mixed with nuclear
extracts. One is the 23-mer oligonucleotide which corresponds
to the sequence of the promoter region of 15-LO-1 including
‘GATA’ (WT-15LO-GATA), and the other is the non-speci¢c
23-mer oligonucleotide including ‘GATA’ (WT-N-GATA).
Both oligonucleotides bound to the nuclear protein prepared
from undi¡erentiated and NaBT-di¡erentiated cells. The ad-
dition of a competitor (100-fold excess) of unlabeled wild-type
oligo-probe completely blocked the binding activity at the
Fig. 1. Expression of GATA-4, 6 and 15-LO-1 in Caco-2 cells. A: Temporal expression after treatment with 5 mM NaBT by Northern blot
analysis using human speci¢c probes of total RNA (20 Wg per sample). Time points are shown at 0, 0.5, 2, 4, 6, 10, 24 h after treatment with
NaBT, respectively. Lane was evaluated by equivalent density of hybridization to the glyceralaldehyde-3-phosphate dehydrogenase (G3PDH)
cDNA. Exposure times for the blots are 72 h, 120 h, 24 h, and 15 h for 15-LO-1, GATA-4, GATA-6, and G3PDH, respectively. B: Immuno-
precipitation and Western analysis. GATA-4 or GATA-6 was immunoprecipitated from 0.3 mg of nuclear protein extract of Caco-2 cells un-
treated or treated with 5 mM NaBT for indicated times (20 h for GATA-4, and 3, 6, 14 and 24 h for GATA-6) and the amount of protein ex-
pression was analyzed by Western analysis. To demonstrate the speci¢city of the band representing GATA-6, 1 Wg of blocking peptide for anti-
GATA-6 or anti-EGFR, as a control, was included in the immunoprecipitation of GATA-6 from some samples.
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GATA site. In contrast, Mu-15-LO-GATA, which has muta-
tions at the GATA site of WT-15LO-GATA, did not compete
with WT-15-LO-GATA for its binding site, suggesting that
there are nuclear binding proteins which recognize and bind
to the GATA site in Caco-2 cells. Moreover, the intensity of
each band in undi¡erentiated cells (FBS) was stronger than
that in di¡erentiated cells (NaBT). Possible explanations for
these observations include: (1) butyrate treatment attenuates
the binding ability at the GATA site, or (2) butyrate treat-
ment decreases the amount of the DNA binding protein at the
GATA site.
3.3. Identi¢cation of GATA-6 as a GATA site binding protein
in undi¡erentiated Caco-2 cells
To identify the nuclear binding protein which bound to the
GATA site, we performed the supershift assay using GATA
antibodies. Incubation with 2 Wg each of GATA-1, 2, 3, 4, 5
or 6 antibody did not result in a supershift band in either
FBS- or NaBT-treated cells (data not shown). However, in-
cubation with GATA-6 antibody remarkably reduced the in-
tensity of the original band in undi¡erentiated cells. The mix-
tures of labeled probe and the nuclear protein were incubated
with various concentrations of the GATA-6 antibody, and
were examined by EMSA (Fig. 3). The original bands (arrow
in Fig. 3) composed of the GATA site oligo-probe and bind-
ing proteins were disrupted by incubation with GATA-6 anti-
body in a concentration-dependent manner in FBS-treated
cells. In contrast, the original band was not a¡ected by incu-
bation with 4 Wg of GATA-6 antibody in NaBT-treated cells.
These observations suggested that GATA-6 protein is bound
to the GATA site in undi¡erentiated Caco-2 cells but not in
NaBT-induced di¡erentiated cells.
3.4. The GATA site of the 15-LO-1 promoter region is
responsible for the basic transcription of 15-LO-1 in
Caco-2 cells
According to the above data, certain proteins, including
GATA-6, bind to the GATA site in the 15-LO-1 promoter.
The next question is whether the GATA site is critical for the
transcription of 15-LO-1. To address that question, a reporter
assay was performed using the promoter/reporter plasmid of
15-LO-1 gene shown in Fig. 4A. Since a single base mutation
in a sequence of ‘GATA’ has a weak binding ability to
GATA-6 protein [36], mutations of ‘GATA’ to ‘TTGA’
were constructed, and designated Mu-628/-23pGL2 as the mu-
tant promoter/reporter plasmid. The mutations were con-
¢rmed by nucleotide sequence analysis (data not shown). Rel-
ative luciferase activity (RLA) was measured in the cells after
treatment with or without NaBT as shown in Fig. 4B. In FBS
alone condition, RLA of Mu-628/-23pGL2 was decreased to
10% of that observed with -628/-23pGL2 (0.50 þ 0.0021
Fig. 2. Existence of a binding protein to the GATA site in Caco-2
cells. EMSA was carried out using nuclear extracts prepared from
Caco-2 cells treated with NaBT for 20 h or FBS alone-treated cells.
Labeled oligonucleotide containing the sequence of the GATA site
required for the transactivation of the 15-LO-1 promoter from posi-
tions 3249 to 3227 from the translational initiation site was used
as a WT probe. Another labeled probe (N) including ‘GATA’ se-
quence but without 15-LO-1 promoter sequence was also used. For
the competitor study, unlabeled WT and Mu probes were used at
100-fold excess. The band of GATA protein and labeled probe com-
plex is shown by an arrow. Unbound labeled probe is also indicated
by an arrow as ‘free probe’.
Fig. 3. GATA-6 bound to the GATA site in the 15-LO-1 promoter
in FBS-treated cells, but not in NaBT-treated cells. A supershift
study was carried out using GATA-6 antibody in FBS alone-treated
cells and cells treated with 5 mM NaBT for 20 h. Labeled WT
probe containing the GATA site was used for the probe template.
Nuclear extracts (5 Wg) and labeled probes were incubated with the
varying concentrations of GATA-6 antibody; 0, 1, 2, 4, and 8 Wg in
FBS-treated cells, and 0 and 4 Wg in NaBT-treated cells. The
GATA-probe complex bands are indicated by an arrow.
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(mean þ S.E.M.) to 0.048 þ 0.019). With NaBT treatment,
RLA was observed with Mu-628/-23pGL2 (0.80 þ 0.095)
only 26% of that observed with -628/-23pGL2 (3.08 þ 0.092).
This observation indicated that the GATA site is important
for the stimulation of 15-LO-1 promoter activity in both
undi¡erentiated and NaBT-induced di¡erentiated Caco-2
cells.
4. Discussion
The expression of 15-LO-1 is not constitutive in all tissues,
and appears to occur during the process of di¡erentiation
[18,20,37^39]. We hypothesized that 15-LO-1 is regulated in
colorectal cells by certain di¡erentiation-related factors, and
focused on the importance of GATA-4/5/6 expression as the
transcription factors since these proteins appear to be associ-
ated with intestinal epithelial cell di¡erentiation [11^16]. We
con¢rmed the presence of a GATA binding site in the 15-LO-
1 promoter of Caco-2 cells. By Northern analysis, the expres-
sion of GATA-4 and 6 was observed, but only GATA-6 ex-
pression was detectable by Western analysis in undi¡erenti-
ated cells (Fig. 1A and B). Interestingly, the expression of
GATA-6 was down-regulated in NaBT-di¡erentiated cells,
measured by both Northern and Western analyses. In con-
trast, expression of 15-LO-1 was up-regulated after treatment
with NaBT. In addition to the study of expression, EMSA
experiments indicated that the nuclear proteins extracted
from Caco-2 cells bind to the GATA binding site present in
the 15-LO-1 promoter region (Fig. 2). The anti-GATA-6 anti-
body we used competitively or allosterically disturbed the
binding of GATA-6 protein to the GATA site in undi¡eren-
tiated cells (Fig. 3). Therefore, GATA-6 is highly expressed
and bound to the GATA site in undi¡erentiated cells (FBS
alone), while GATA-6 protein is not detected in di¡erentiated
cells (NaBT). These results suggest that down-regulation of
GATA-6 expression is likely to be linked to the regulation
Fig. 4. Mutations of the GATA site in the promoter/reporter construct of 15-LO-1 attenuates luciferase activity. A: Promoter/reporter con-
struct of 15-LO-1 gene. The fragment of 5P £anking region from 3628 to 323 of 15-LO-1 promoter was constructed in pGL2 basic luciferase
reporter plasmid as -628/-23pGL2, which contains the GATA binding site at 3240 position. The GATA binding site of -628/-23pGL2 was mu-
tated by site-directed mutagenesis and the mutant promoter/reporter plasmid is designated as Mu-628/-23pGL2. B: Luciferase activity of 15-
LO-1 promoter in Caco-2 cells by treatment with or without 5 mM NaBT. Caco-2 cells were transiently transfected with -628/-23pGL2 or Mu-
628/-23pGL2 and pRL-null and then incubated for 48 h. Luciferase activity was measured and expressed as the RLA (relative luciferase activ-
ity): LAF (¢re£y luciferase signal)/LAR (renilla luciferase signal).
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of 15-LO-1 expression, possibly as a negative regulator (re-
pressor) for 15-LO-1 gene.
On the other hand, the reporter assay using constructs with
mutations of its GATA binding site at 3240 in the 15-LO-1
promoter region (Fig. 4) supports the conclusion that the
GATA site is responsible for the stimulation of 15-LO-1 pro-
moter activity in both undi¡erentiated and NaBT-induced
di¡erentiated cells.
Based on these data, the following two hypotheses are pro-
posed: (1) GATA-6 represses the expression of 15-LO-1 by
binding the GATA site of the 15-LO-1 promoter. (2) There
are uncharacterized proteins of the GATA family, or related
proteins, which bind to the GATA site and activate the 15-
LO-1 expression both in undi¡erentiated and NaBT-di¡eren-
tiated Caco-2 cells. Mano et al. reported that a down-regula-
tion of GATA-6 is an essential feature for the phenotypic
modulation of vascular smooth muscle cells [40]. GATA-6
appears to function primarily within the proliferating progen-
itor population in the process of intestinal cell di¡erentiation
in HT-29 cells [11]. In addition, a reduced GATA-6 level is
reported in the progression of the cardiomyogenic di¡erentia-
tion program [41]. GATA proteins also repress PU.1 trans-
activation of critical myeloid target genes [42]. These reported
¢ndings suggest GATA transcription factors act as repressors
for target genes. In our study, a disruption model (knockout
model) of GATA-6 would be more informative to clarify the
precise function of GATA-6 for the regulation of 15-LO-1
expression.
In contrast, not only GATA-6, but also GATA-4, 5 are
implicated in adrenocortical tumorigenesis [43], in the myo-
cardial gene expression [44], and in the regulation of cardiac
morphogenesis [45]. We were not able to delete the GATA
binding shift band using another antibody against GATA-1,
2, 3, 4, or 5 in the NaBT-treated condition (data not shown).
However, we can not exclude the possibility that the antibod-
ies used in our study did not recognize DNA-bound proteins
very well. The second explanation for our results is that novel
GATA site binding proteins such as FOG (friend of GATA)-1
[46] and FOG-2 [47] are bound to the GATA binding site of
the 15-LO-1 promoter instead of the conventional GATA-1^
6. Thus, transcriptional regulation of 15-LO-1 by the GATA
family is still complex and not well understood. In future
studies, post-translational modi¢cations, such as phosphory-
lation [48] or acetylation [49,50], of GATA family must be
considered in order to clarify the regulation of 15-LO-1 in
intestinal derived cells.
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